-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article source: Medical Rubik's Cube Info
Author: Sunshine
Recently, Pfizer and BioNTech announced that the COVID-19 vaccine Comirnaty (tozinameran, BNT162b2) for use in children aged 5-11 has received an emergency use authorization (EUA) from the FDA
.
For this age group, the dosage regimen is: a dose of 10 µg, with a second injection at 21 days intervals
The FDA's decision is based on data from a Phase II/III clinical trial
.
A total of 4,500 children aged 5-11 years were enrolled in the study
Pfizer and BioNTech have submitted authorization requests for the COVID-19 vaccine for this age group to global regulatory agencies such as the European Medicines Agency
.
At present, there are two clinical trials of Comirnaty for children (2-5 years old, 6 months-2 years old) are underway, and initial data will be released in the fourth quarter of 2021 or the first quarter of 2022 at the earliest
Note: The original text has been deleted